Response
| . | Both treatment arms . | FND . | ATT . | P . |
|---|---|---|---|---|
| Evaluable | 142 | 73 | 69 | |
| CR (%) | 90 (63) | 49 (67) | 41 (59) | .233-150 |
| CRu (%) | 28 (20) | 9 (12) | 19 (28) | |
| PR (%) | 20 (14) | 13 (18) | 7 (10) | |
| SD (%) | 1 (1) | 0 (0) | 1 (1.5) | |
| PD (%) | 3 (2) | 2 (3) | 1 (1.5) | |
| CR + CRu + PR (%) | 138 (97) | 71 (97) | 67 (97) |
| . | Both treatment arms . | FND . | ATT . | P . |
|---|---|---|---|---|
| Evaluable | 142 | 73 | 69 | |
| CR (%) | 90 (63) | 49 (67) | 41 (59) | .233-150 |
| CRu (%) | 28 (20) | 9 (12) | 19 (28) | |
| PR (%) | 20 (14) | 13 (18) | 7 (10) | |
| SD (%) | 1 (1) | 0 (0) | 1 (1.5) | |
| PD (%) | 3 (2) | 2 (3) | 1 (1.5) | |
| CR + CRu + PR (%) | 138 (97) | 71 (97) | 67 (97) |
P compares CR + CRu rates between FND and ATT treatment arms.